There is now enough evidence of ‘extra‐glycaemic’ benefits of SGLT-2 inhibitors on cardiovascular and renal function to justify them being used irrespective of glycaemic control, Australian experts say. The presence of comorbidities such as atherosclerotic cardiovascular disease, heart failure and chronic kidney disease (CKD) should guide the use of SGLT2 inhibitors rather than HbA1c levels ...
Cardioprotective SGLT2 inhibitors should be used based on risk, not glycaemia: experts
By Michael Woodhead
21 May 2020